INtRODUCtION
The number of secretory cells present in mammary tissue at the onset of lactation is key in determining potential sow milk yield (Head and Williams, 1991) . This is important because piglet growth rate is limited by the amount of milk produced by the sow (Harrell et al., 1993) . Rapid mammary accretion takes place during the last third of gestation (Sorensen et al., 2002) and can be affected by numerous factors. In rodents, obesity has a negative impact and also reduces mammary expression of various milk protein genes (Hernandez et al., 2012) . When altering body composition in swine by manipulating protein and energy intakes during gestation, overly fat and leaner gilts had similar mammary weights on d 112 of gestation but there was a drastic reduction in DNA concentration in overly fat gilts (Head and Williams, 1991) . On the other hand, fatter gilts from a Meishan cross had less mammary parenchymal tissue and lower parenchymal DNA concentrations than thinner Large White gilts in late gestation (Farmer ABStRACt: The impact of body condition at 110 d of gestation on mammary gland development, mammary gene expression, and hormonal and metabolite status of gilts was studied. Thirty-nine gilts were equally divided into 3 groups based on their backfat thickness at the end of gestation: 1) low backfat (LBF; 12-15 mm), 2) medium backfat (MBF; 17-19 mm), or 3) high backfat (HBF; 21-26 mm). Gilts had similar BW (138.1 ± 8.2 kg) and backfat thicknesses (16.4 ± 1.0 mm) at mating and the 3 groups were achieved via ingestion of varying amounts of feed throughout gestation. Jugular blood samples were obtained from all gilts at mating and at 109 d of gestation to assess hormonal and metabolic statuses, and animals were slaughtered on d 110 to collect mammary glands for compositional analyses and for measure of gene expression. The LBF gilts had less extraparenchymal tissue (P < 0.01) and parenchymal tissue (P < 0.05) than HBF gilts.
Mammary parenchyma from LBF gilts also tended to contain less DM (P < 0.10), contained more protein (P < 0.05), and had greater RNA concentrations (P < 0.01) than that from HBF gilts. None of the 15 genes studied in mammary parenchymal tissue differed in terms of expression level, and the rate of mammary cell proliferation was similar among treatments (P > 0.10). There was a tendency for circulating leptin concentrations on d 109 of gestation to be lower in LBF gilts than in MBF gilts (P < 0.10), whereas values for HBF gilts did not differ from those of the other treatments (P > 0.10). Current results demonstrate that being too thin at the end of gestation (12-15 mm backfat) has a negative impact on mammary development in gilts, whereas having backfats varying from 17 to 26 mm seems to have no detrimental effects on mammogenesis. Backfat thickness in late pregnancy must therefore be considered to achieve optimal sow lactation performance. et al., 2000) . Differences in expression levels of specific genes related to mammary gland development were also observed in the mammary parenchymal tissue of UptonMeishan and Large White gilts (Palin et al., 2002) . Such data, however, do not exist for thinner animals representing body conditions that are seen commercially (Tarrés et al., 2006) .
Recent data indicate a relationship between sow body condition in late gestation and litter performance (Kim et al., 2015; Rempel et al., 2015) and between fatness of sows and colostrum yield , and milk quality (Rekiel et al., 2011) and quantity (Revell et al., 1998) . Body condition in late pregnancy should be considered to improve sow lactation performance but there is a lack of information on its link with mammary development. The goal of this project was to study the impact of body conditions that are seen commercially at the end of gestation on mammary development and mammary gene expression in gilts.
MAtERIALS AND MEtHODS
Animals were cared for according to the national guidelines for the care and use of animals (CCAC, 2009) and procedures were approved by the Institutional Animal Care Committee of the Sher brooke Research and Development Centre of Agriculture and Agri-Food Canada.
Animals and Treatments
Sixty-four (Yorkshire × Landrace) × Yorkshire gilts were bred via AI using pools of semen from 50 Duroc boars of proven fertility. Of these animals, 17 were discarded because they did not meet the backfat criteria detailed below, 5 because they were not pregnant, and 3 for health reasons. At mating (2 on first heat, 30 on second heat, and 7 on third heat), the remaining 39 gilts had similar body conditions (i.e., backfat thickness of 16.4 ± 1.0 mm) and they were assigned to the following 3 treatments based on backfat thickness to be achieved by d 110 of gestation: 1) low backfat (LBF; 12-15 mm; n = 13), 2) medium backfat (MBF; 17-19 mm; n = 13), and 3) high backfat (HBF; 21-26 mm; n = 13). Gestating gilts were housed in individual pens (1.5 by 2.4 m) and were fed different amounts of a conventional diet (12.84 MJ/kg DE, 13.71% CP, and 0.61% lysine) to obtain varying fat deposition. The amounts of feed provided are shown in Table 1 , and gilts were fed in one meal at 0800 h. All animals were weighed and had their backfat thickness ultrasonically measured (Vetkoplus; NOVEKO Int., Lachine, QC, Canada) at P2 of the last rib at mating and on d 30, 50, 70, 100, and 109 of gestation before the morning meal. Jugular blood samples were obtained from all gilts at mating and on d 109 of gestation. Gilts were then slaughtered on d 110 of gestation to obtain mammary glands for compositional analyses and samples of parenchymal tissue for gene expression analyses. Their uterus was removed and fetuses were counted; ovaries were also obtained and weighed and the number of corpora lutea was counted. The experiment took place between September 2013 and April 2014.
Blood Handling and Assays
Blood samples were used to measure concentrations of urea, free fatty acids (FFA), glucose, insulin, leptin, adiponectin, estradiol, and IGF-1. Blood sampling was done between 0700 and 0800 h before the morning meal. Blood samples for urea, leptin, and adiponectin (40 mL) were collected into Vacutainer tubes without anticoagulant (Becton, Dickinson and Company, Franklin Lakes, NJ) and left at room temperature for 4 h, stored overnight at 4°C, and centrifuged for 12 min at 1,800 × g at 4°C the following day, and serum was then harvested. Blood samples for FFA, estradiol, IGF-1, and insulin assays (20 mL) were collected in EDTA tubes (Becton Dickinson and Company, Rutherford, NJ), put on ice, and centrifuged within 20 min for 12 min at 1,800 × g at 4°C, and plasma was immediately recovered. Lastly, blood samples for glucose analyses were collected into tubes containing 10.0 mg of potassium oxalate and 12.5 mg of sodium fluoride to inhibit glycolysis, put on ice, and centrifuged within 20 min at 1,800 × g for 12 min at 4°C, and plasma was immediately recovered. Serum and plasma samples were fro- zen at −20°C until assayed. Insulin was measured with a porcine insulin commercial RIA kit (EMO Millipore Corporation, St. Charles, MO), which was previously validated for sow serum (Farmer et al., 2010) . Sensitivity of the assay was 14.4 pmol/L and intra-and interassay CV were 6.71 and 7.26%, respectively. Leptin was measured with a multispecies commercial RIA kit (EMO Millipore Corporation, St. Charles, MO), which was previously validated for sow serum (Farmer et al., 2010) . Sensitivity of the assay was 1.0 ng/mL, and intraand interassay CV were 5.04 and 5.28%, respectively. Concentrations of adiponectin were determined using a porcine adiponectin ELISA Kit (Cusabio Biotech Co., Ltd., Wuhan, P.R. China). Sensitivity of the assay was 1.88 μg/mL, and the intra-and interassay CV were 2.40 and 3.73%, respectively. Concentrations of IGF-1 were measured with a commercial kit for humans (ALPCO 26-G; ALPCO Diagnostics, Salem, NH) with small modifications as previously detailed (Plante et al., 2011) .
Validation for a plasma pool from sows was previously conducted (Plante et al., 2011) . Sensitivity of the assay was 0.10 ng/mL. The intra-and interassay CV were 6.11 and 1.46%, respectively. Due to large differences in the range of values for estradiol between the 2 blood samples, 2 different commercial kits had to be used. For values at mating, an ultrasensitive kit was used (Beckman Coulter Canada Inc., Montréal, QC, Canada) and the intra-and interassay CV were 6.70 and 5.96%, respectively. For values at the end of gestation, a standard estradiol kit was used (MP Biomedicals, Orangeburg, NY) and the intra-and interassay CV were 5.67 and 1.87%, respectively. Glucose was measured by an enzymatic colorimetric method with a commercial kit (Sekisui Diagnostics, Charlottetown, PEI, Canada). Intra-and interassay CV were 0.85 and 1.03%, respectively. Urea was measured by colorimetric analysis using an auto analyzer (Auto-Analyzer 3; Technicon Instruments Corp., Tarrytown, NY) according to the method of Huntington (1984) . Intra-and interassay CV were 2.70 and 2.76%, respectively. Concentrations of FFA were also measured by colorimetry with a commercial kit (Wako Chemicals USA, Inc., Richmond, VA). Intra-and interassay CV were 1.75 and 1.44%, respectively.
Mammary Gland Measurements
At slaughter, mammary glands from both sides of the abdominal wall were excised. Those from one side of the udder were stored at −20°C and, once frozen, were cut into 2-cm slices and stored again at −20°C. Each slice was later trimmed of skin and teats, and mammary parenchymal tissue was dissected from surrounding adipose tissue (i.e., extraparenchymal tissue) at 4°C. Both parenchymal and extraparenchymal tissue weights from this side of the udder were recorded. Parenchymal tissue from all dissected and sliced glands was homogenized and a representative sample was used for determination of composition by chemical analysis. The RNA content of parenchymal tissue was measured by UV specto photometery (Volkin and Cohn, 1954) and the DNA content of parenchymal tissue was evaluated in all samples using a method based on fluorescence of a DNA stain (Labarca and Paigen, 1980) . Dry matter, protein, and lipid contents were also determined (methods 950.46, 928.08, and 991.39, respectively; AOAC, 2005) in parenchyma. The other side of the excised mammary glands was used for gene expression analyses and to perform the Ki-67 proliferation assay. Parenchymal tissue samples from the fourth teat were collected from 8 gilts per treatment to assess mammary cell proliferation. Proliferating cells were identified by immunohistochemistry using a mouse anti-Ki-67 antibody, as previously reported (Farmer et al., 2014) . A representative sample of parenchyma was obtained from the fourth teat to measure the relative mRNA abundance for adiponectin (ADIPOQ), adiponectin receptor 1 and 2 (ADIPOR1 and ADIPOR2), caveolin 1 (CAV1), β-casein (CSN2),
IGF-1, leptin (LEP), long form of leptin receptor (LEPR), mechanistic target of rapamycin (MTOR), prolactin (PRL), long form of the prolactin receptor (PRLR-LF)
, suppressor of cytokine signaling 1 and 3 (SOCS1 and SOCS3), signal transducers and activators of transcription 5A and 5B (STAT5A and STAT5B), and whey acidic protein (WAP). These genes were selected based on their known or suspected role in mammary gland development and lactation (Park et al., 2002; Piantoni et al., 2010; Bionaz et al., 2012) . Tissue samples were frozen immediately in liquid nitrogen and stored at −80°C.
The RNA Extraction, Complementary DNA Synthesis, and Real-Time PCR Amplifications of Studied Genes
Total RNA was extracted from parenchymal tissue using the TRIzol reagent (Invitrogen Life Technologies, Burlington, ON, Canada). Concentration, quality, and integrity of extracted RNA were determined using a NanoDrop Spectrophotometer ND-1000 (NanoDrop Technologies Inc., Wilmington, DE) and a 1% agarose gel electrophoresis. Reverse transcription was performed as previously described (Labrecque et al., 2009) .
The relative mRNA abundance of studied genes (ADIPOQ, ADIPOR1, ADIPOR2, CAV1, CSN2, LEP, LEPR, MTOR, PRL, SOCS1, SOCS3, STAT5A, STAT5B , and WAP) was determined using real-time PCR amplifications. Forward and reverse primers were designed using the Primer Express Software Version 3.0 (Applied Biosystems, Foster City, CA) and are listed in Table 2 .
Reactions were performed in a 10-μL reaction volume (except for detection of PRL, LEP, and SOCS-1, which were adjusted to 25 μL) consisting of 1 μL of corresponding concentrations of forward and reverse primers (Table 2) , 5 μL of 2x SYBR Green Master Mix (PE Applied Biosystems), 3 μL of 15x diluted cDNA, and 0.05 μL of uracil N-glycosylase AmpErase (PE Applied Biosystems). Cycling conditions consisted of 2 min at 50°C to activate the uracil N-glycosylase AmpErase followed by 10 min at 95°C and 40 repetitive cycles of 15 s at 95°C and annealing and polymerization for 45 s at 60°C in an ABI 7500 Fast Real-Time PCR System (PE Applied Biosystems). Amplifications were performed in triplicate, and specificity of amplified fragments was verified using the melting curve analysis. Standard curves were composed of serial dilutions of complementary cDNA pools (Labrecque et al., 2009 ) and were assayed in duplicate for each gene to obtain the relative quantification of mRNA using the standard curve method (Applied Biosystems, 1997 (Table 2) to identify those that were the least affected by treatments. Using the NormFinder algorithm (Andersen et al., 2004) , the geometric mean of GAPDH and PPIA was identified as the least affected by treatment and was used as a normalization factor. For each experimental sample, the mRNA abundance of studied genes relative to the reference genes was determined from their respective standard curves. The relative quantity ratios were calculated by dividing the relative quantity units of studied genes by those of the normalization factor. Mean values from triplicates were then used to perform statistical analyses.
Statistical Analyses
The MIXED procedure of SAS (SAS Inst. Inc., Cary, NC) was used for statistical analyses. The univariate model (with 3 levels) used for mammary gland composition and real-time PCR data included the effect of treatment, with the residual error being the error term used to test main effects of treatment. Repeated measures ANOVA with the factors treatment (the error term being gilt within treatment) and day of gestation (the residual error being the error term) and the treatment × day interaction were also performed on hormonal and metabolic data. Separate ANOVA for each day were also performed on these variables. Data in tables are presented as least squares means ± maximal SEM, except when otherwise mentioned.
RESULtS
Feed allowances of gilts during gestation are shown in Table 1 , and their age at mating, BW, and backfat thicknesses are shown in Table 3 . Average age at mating was not affected by treatments (Table 3 ; P > 0.10). Weights and backfats were similar at mating across treatment (P > 0.10), differed between LBF and HBF gilts on d 30 of gestation (P < 0.05), and differed among all 3 treatment groups on d 50, 70, 100, and 109 of gestation (P < 0.05). Litter size was 11.5 ± 4.0, 13.1 ± 3.4, and 13.5 ± 3.9 for LBF, MBF, and HBF gilts, respectively. Average fetal weight on d 110 of gestation (weighted for litter size) did not differ among treatments (P > 0.10), being 1.07, 1.08, and 1.16 ± 0.05 kg for LBF, MBF, and HBF gilts, respectively. Average weight of ovaries as well as mean number of corpora lutea also did not differ among treatments (P > 0.10, data not shown).
Metabolic and endocrine variables are shown in Table 4 . There was a treatment effect on circulating IGF-1 concentrations because these were lower at mating in MBF gilts (P < 0.05) than in LBF or HBF gilts, yet this effect was no longer present on d 109 of gestation (P > 0.10). There was a tendency for leptin concentrations to be affected by treatment on d 109 of gestation, with values being lower for LBF gilts than for MBF gilts (P < 0.10). There were no differences in concentrations of estradiol, adiponectin, urea, FFA, glucose, or insulin due to treatments (P ≥ 0.10). There was a day of sampling effect on all measured variables, except FFA. Values for glucose, insulin, adiponectin, and IGF-I decreased (P < 0.01) between mating and d 109 of gestation, whereas those for estradiol (P < 0.01) and urea (P < 0.05) increased. There was a treatment × day of sampling interaction (P = 0.01) for leptin so that values increased between mating and d 109 of gestation in MBF and HBF gilts but not in LBF gilts (Table 4) .
Data on mammary composition and parenchymal gene expression are shown in Table 5 . Low backfat gilts had less extraparenchymal tissue (P < 0.01) than MBF or HBF gilts and had less parenchymal tissue (P < 0.05) than HBF gilts. There were also changes in composition of parenchymal tissue. Mammary parenchyma from LBF gilts tended to contain less DM (P < 0.10) and contained more protein (P < 0.05) and RNA (P < 0.01) than that from HBF gilts. Total parenchymal fat was also lesser in LBF gilts than in MBF or HBF gilts (P < 0.01). None of the 15 genes studied in mammary parenchymal tissue differed in terms of expression level (P > 0.10). Data for LEPR are not presented in Table 5 because this transcript was barely detectable in mammary parenchymal samples and its relative mRNA abundance could not be estimated using real-time PCR assays. Percent of Ki-67-positive 1 ADIPOQ = adiponectin; ADIPOR1 and ADIPOR2 = adiponectin receptors 1 and 2; CAV1 = Caveolin-1; CSN2 = β-casein; IGF-1 = insulin-like growth factor 1; LEP = leptin; LEPR (Ob-Rb) = long form of the leptin receptor; mTOR = mechanistic target of rapamycin; PRL = prolactin; PRLR-LF = long form of the prolactin receptor; SOCS1 and SOCS3 = suppressor of cytokine signaling 1 and 3; STAT5A and STAT5B = signal transducers and activators of transcription 5A and 5B; WAP = whey acidic protein = GAPDH = glyceraldehyde = 3-phosphate dehydrogenase; MRPL39 = mitochondrial ribosomal protein L39; PPIA = peptidylprolyl isomerase A (Cyclophilin A); UBC = ubiquitin C; VAPB = vesicle-associated membrane protein-associated protein B/C. 2 F = forward; R = reverse.
cells, used to assess proliferation rate, also did not differ among treatments (2.23, 2.57, and 2.72 ± 0.33 for LBF, MBF, and HBF, respectively; P > 0.10).
DISCUSSION
Current results provide the first demonstration that being too thin at the end of gestation (12-15 mm backfat) has a negative impact on mammary development in gilts. This deleterious effect was characterized by a reduction in mammary parenchymal tissue mass. On the other hand, gilts with backfat thicknesses of either 17 to 19 mm or 21 to 26 mm on d 109 of gestation did not show an inhibition in mammary development. This is in agreement with findings from Smits et al. (1995) , who saw no effect of sows having 18 or 24 mm of backfat at the end of pregnancy on their mammary DNA concentration. It also corroborates findings of Howard et al. (1994) , who reported no effect of body fat accretion during gestation on mammary development in pregnant gilts that were fed adequate or increased energy levels. Furthermore, it supports results of Beyga and Rekiel (2010) , who noted that sows with average backfat thicknesses of 15.2 mm compared with sows with average backfat thicknesses of 26.2 mm in late pregnancy had a reduced average piglet weight at weaning. The HBF group (21-26 mm) in the current study could be considered fat but not obese. Indeed, this level of fatness did not have the detrimental effects on mammary development or milking performances that are seen in obese rodents (Flint et al., 2005; Hernandez et al., 2012) or in gilts with a backfat thickness of 36 mm in late gestation (Head and Williams, 1991) or sows with a backfat thickness over 25 mm on d 109 of gestation (Kim et al., 2015) . The levels of backfat thickness in the present study are lower than in those 2 latest reports, so that they better represent what is seen commercially (Tarrés et al., 2006) . Contrary to what was seen by Head and Williams (1991) in obese gilts, the reduced mammogenesis in LBF gilts in the current study was not due to a lower DNA concentration or a decreased cell proliferation, thereby suggesting a possible link with cell size. Weldon et al. (1991) also table 3. Age at mating and BW and backfat thicknesses throughout gestation for gilts achieving a low backfat (LBF; 12-15 mm; n = 13), medium backfat (MBF; 17-19 mm; n = 13), or high backfat (HBF; 21-26 mm; n = 13) at 110 d of gestation Means within a row with different superscripts tend to differ (P < 0.10).
1 Maximum value.
2 Day of sampling effect (P < 0.01).
3 Day of sampling effect (P < 0.05).
4 Day of sampling × treatment interaction (P = 0.01).
noted that a 21% decrease in parenchymal weight due to increased dietary energy as of d 75 of gestation was not linked with differences in parenchymal DNA concentrations on d 105 of gestation. Interestingly, the reduction in parenchymal weight observed in the present trial was accompanied by increases in protein percent and RNA concentrations in the parenchymal tissue. This suggests a potential beneficial effect in terms of metabolic activity, which may be an attempt to counterbalance the inhibition in mammary development. Yet Weldon et al. (1991) saw a tendency for reduced protein concentration in mammary parenchyma from gilts that were overly fed energy in late gestation. It may be that the effects of feed restriction on mammary metabolism (present trial) are different from those of overfeeding (trial of Weldon et al., 1991) . However, such a hypothesis needs to be further investigated. Few studies were performed to look at the effect of poor body condition on mammary development in pigs. During the prepubertal phase of rapid mammary accretion, it was shown that a 20% feed restriction, leading to a backfat thickness of 15.5 mm at 203 d of age instead of 22.6 mm for unrestricted gilts, had a detrimental effect on mammogenesis characterized by a 26% reduction in parenchymal tissue mass (Farmer et al., 2004) . There were also indications that a poorer body condition (16.1 vs. 17.5 mm backfat) on d 108 of gestation leads to impaired mammary development, as shown by a 26% reduction in mammary parenchymal mass (Farmer et al., 2014) .
The beneficial role of IGF-1 for stimulating mammary development in pubertal animals is documented (Kleinberg and Ruan, 2008) , and there are also indications that it may be involved in mammogenesis taking place during pregnancy (Hadsell et al., 2002 ). Yet its role in the pregnant pig is not clear. Current results showed no significant effect of body condition on IGF-1, yet on d 109 of gestation, there was a large numerical increase (21%) in IGF-1 concentrations of LBF gilts compared with gilts from the other 2 groups (MBF and HBF). This was unexpected due to the lower growth rate of LBF animals. DeHoff et al. (1986) suggested that growth hormone may not be mammogenic in the pig during pregnancy, and present results seem to corroborate that. Previous findings also showed that an impaired mammary development, tied with lower backfat thickness, at the end of gestation was not related to altered circulating IGF-1 concentrations (Farmer et al., 2014) . Amdi et al. (2014) further demonstrated that thin gilts at mating (12 mm) had serum IGF-1 concentrations similar to those of fat gilts (19 mm) on d 80 of gestation but that their offspring showed poorer growth performances. The tendency for reduced concentrations of leptin in LBF gilts was expected due to the fact that leptin is mainly produced by adipocytes and then secreted in the bloodstream. In fact, a treatment effect would also have been expected between LBF and HBF gilts. Indeed, reported that fat sows (>22 mm backfat) had greater circulating concentrations of leptin than moderate (18-22 mm) or lean (<18 mm) sows in the peripartal period. On the other hand, Batorek et al. (2013) suggested that there is no direct relation between circulating leptin concentrations and backfat thickness in sows at weaning (d 28 of lactation). In the current study, there was no correlation between circulating leptin and backfat thickness at mating or d 109 of gestation (data not shown). The observed tendency for lower circulating leptin in gilts having less mammary parenchyma is of interest because it means that, contrary to what is seen in heifers fed highenergy diets (Silva et al., 2002) , the negative impact of poor body condition on mammary development is not mediated by increased leptin. In rodents, creating a state of obesity via feeding a high-fat diet impaired mammary development and decreased mRNA expression of milk protein genes (Hernandez et al., 2012) . A relationship between CSN2 expression and mammary development in late-pregnant gilts was also suggested (Farmer et al., 2014) . It is therefore surprising that the impaired mammogenesis observed in LBF gilts was not linked with changes in expression level of the CSN2 gene. Alterations in relative mRNA abundance for other genes was also expected because of the previous relationship noted between mammary parenchymal weight and expression level of IGF-1, STAT5B, and WAP genes in late-pregnant gilts (Farmer et al., 2014) . Differences in mammary parenchymal expression of the STAT5A (but not STAT5B) gene were also noticed in late pregnancy among breeds with different backfat thicknesses; values were less in the leaner Large White compared with the fatter Meishan-derived gilts (Palin et al., 2002) . It therefore seems that factors other than body condition are involved in the regulation of parenchymal expression of the studied genes.
The fact that fetal weights on d 110 of gestation were not affected by treatments corroborates findings of King et al. (2006) whereby feeding level (varying from 2.2 to 3.8 kg/d) from mid to late gestation did not alter birth weight of piglets even though it increased weight gain of gilts. In conclusion, current findings indicate that being too thin at the end of gestation (12-15 mm backfat) has a negative impact on mammary development in gilts, whereas having backfats varying from 17 to 26 mm likely has no detrimental effects on mammogenesis. This is important for swine producers because the feeding strategy used in gestation may directly impact body condition. It is of great interest because the only published report to date on the effect of body condition on mammary development in swine is that of Head and Williams (1991) and was performed with obese gilts. Even though backfat thicknesses below 15 mm are not common, they can be seen in gilts, and Amdi et al. (2014) also used an average backfat of 12 mm as the descriptor for thin gilts. The relative importance of body size vs. backfat thickness for mammary development in gilts merits further investigation as well as the comparison of achieving varying body conditions in late gestation due to gestation feeding or to different backfat thickness at mating.
